Bayhill Therapeutics to Present Phase II Follow-up Data on BHT-3009 for Treatment of Multiple Sclerosis
Abstract Accepted for 61st Annual American Academy of Neurology (AAN) Meeting
Survey Protocol Data Demonstrate Reduction in Relapse Rates and Decreases in Brain Lesions
SAN MATEO, Calif.--(BUSINESS WIRE)--Bayhill Therapeutics Inc., a clinical-stage biopharmaceutical company leveraging its proprietary BHT-DNA™ platform to develop novel and targeted autoimmune disease treatments, today announced that an abstract titled “One Year Follow-up Results from a Phase II Trial of the BHT-3009 DNA Vaccine for Multiple Sclerosis,” has been accepted for presentation at the 61st Annual American Academy of Neurology (AAN) meeting, to be held in Seattle, Washington from April 25 through May 2, 2009.
Data in the abstract indicates that BHT-3009 has a durable effect and continues to have a favorable safety profile for up to 12 months following the completion of dosing. BHT-3009 is an antigen-specific plasmid encoding myelin basic protein (MBP) that aims to reprogram the immune system to tolerize to, rather than attack, myelin antigens in the central nervous systems of multiple sclerosis (MS) patients.